undamentalytics Newsletter
Sign in

Bioaffinity Technologies, Inc. revenue

Bioaffinity Technologies, Inc.'s revenue was $6.2m in fiscal 2025, down 34.2% on the year before. Since fiscal 2022 ($6.9m) it has grown at a compound -3.7% a year. Over the last twelve months it was $5.9m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue6,9007,9009,3626,1625,901
Growth on the year before—+14.5%+18.5%−34.2%—
Gross profit4————
Gross margin0.1%————

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Laboratory Services $6.2M 99.9% ▼ 34.1%
Health Care Patient Service $5M 80.7% ▼ 39.2%
Histology Service Fees $1.1M 18.1% ▲ 1.2%
Medical Director Fees $68,268 1.1% ▲ 2.5%
Other Revenues $4,860 0.1% ▼ 34.1%
Department of Defense Observational Studies $577 0.0% ▼ 93.3%
Diagnostic Research and Development $577 0.0% ▼ 93.3%

From Bioaffinity Technologies, Inc.'s 10-K filed March 16, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Bioaffinity Technologies, Inc. $5.9m -23.2% -12.2%
Lucid Diagnostics Inc. $5.4m 24.9% 90.1%
Neuraxis, Inc $5.3m 65.2% 25.6%
Charming Medical Ltd $4.8m -22.7% —
Invo Fertility, Inc. $7.5m 13.8% 85.6%
Beyond Air, Inc. $7.7m 60.7% 122.7%

Compare with peers

Head to head: BIAF vs LUCDBIAF vs NRXSBIAF vs MCTA

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Bioaffinity Technologies, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bioaffinity Technologies, Inc.